IP Library › Granted Patent US 9,012,693
Granted Patent B2
US 9,012,693 · App. 13/119,585 · Granted Apr 21, 2015

Process for the preparation of vitamin K2

Inventors: Lars Skattebol (Jar, NO); Inger Reidun Aukrust (Oslo, NO); Marcel Sandberg (Oslo, NO)
Assignee: Kappa Bioscience AS
C07C41/18C07C41/22C07C41/26C07C41/30C07C46/02C07C50/14C07C315/04C07C319/20C07C17/16C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,012,693
App. No.
13/119,585
Granted
Apr 21, 2015
Kind
B2
Abstract

Using a combination of Kumada, Suzuki and Biellmann chemistry, various menaquinones can synthesized rapidly and with stereochemical integrity offering a new way of preparing these vitamin K2 components for the pharmaceutical market. In one embodiment a process for the preparation of a compound of formula (I) is defined including a step in which (i) a compound of formula (II) is reacted formula (III) wherein R is an alkyl group; LG is a leaving group; m is an integer from 0 to 8; n is an integer from 0 to 9; and X is hydrogen, halide, hydroxyl or protected hydroxyl; in the presence of a copper, nickel or palladium catalyst.

Claims (44)

1. A process for the preparation of a compound of formula (I)

comprising a step in which (i) a compound of formula (II) is reacted with a compound of formula (III)

wherein R is an alkyl group;

LG is a leaving group;

m is an integer from 0 to 8;

n is an integer of from 0 to 9; and

X is hydrogen, halide, hydroxyl or protected hydroxyl;

in the presence of a palladium catalyst;

(ii) if necessary, converting X into a leaving group;

(iii) reacting with a compound (V) or (VI)

wherein Ar is aryl and m is independently as hereinbefore defined in the presence of a base;

(iv) reducing the —SO 2 Ar or SAr group in the resulting compound to a hydride; and

(v) converting the diprotected naphthoquinone into a naphthoquinone.

2. A process as claimed in claim 1 wherein step (v) is achieved using cerium ammonium nitrate (CAN).

3. A process as claimed in claim 1 wherein the reaction of a compound of formula (II) with a compound of formula (III) results in compound (I′) in which X is hydrogen

4. A process as claimed in claim 3 in which a terminal hydrogen (i.e. the hydrogen at the X position) is converted to hydroxyl using selenium dioxide and thereafter converted to a leaving group, e.g. a halide to thereby facilitate step (ii).

5. A process for the preparation of a compound of formula (I)

comprising a step in which (i) a compound of formula (II) is reacted with a compound of formula (III)

wherein R is an alkyl group;

LG is a leaving group;

m is an integer from 0 to 8;

n is an integer of from 0 to 9; and

X is hydrogen, halide, hydroxyl or protected hydroxyl;

in the presence of a palladium catalyst;

(ii) converting X into a SPh or —SO 2 Ph group to form compound (VII)

wherein m is independently as hereinbefore defined;

(iii) deprotonating (alpha to the sulphur) and reacting with a compound

wherein m is independently as hereinbefore defined;

(iv) reducing the phenylthioether or —SO 2 Ph to hydrogen; and

(v) converting the diprotected naphthoquinone into a naphthoquinone ring.

6. A process for the preparation of a compound of formula (I)

comprising a step in which (i) a compound of formula (II) is reacted with a compound of formula (III)

wherein R is an alkyl group;

LG is a leaving group;

m is an integer from 0 to 8;

n is an integer of from 0 to 9; and

X is hydrogen, halide, hydroxyl or protected hydroxyl;

in the presence of a palladium catalyst;

(ii) if necessary converting X into a leaving group;

(iii) reacting with a compound

wherein m is independently as hereinbefore defined;

in the presence of a Pd catalyst; and

(iv) converting the diprotected naphthoquinone into a naphthoquinone.

7. A process as described in claim 1 wherein the compound of formula (I) is MK-7

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2011
From: SKATTEBOL, LARS; AUKRUST, INGER REIDUN; SANDBERG, MARCEL
To: KAPPA BIOSCIENCE AS
Reel/Frame 026209/0628 →
Priority Claims (1)
GB 0817528.3 · Sep 24, 2008 · national
Continuity (1)
Related Publication 20110207967A1 · Aug 25, 2011